---
document_datetime: 2025-12-02 04:50:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-viatris-pharma.html
document_name: pregabalin-viatris-pharma.html
version: success
processing_time: 0.1133972
conversion_datetime: 2025-12-27 15:44:38.22041
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

[RSS](/en/individual-human-medicine.xml/65716)

##### Authorised

This medicine is authorised for use in the European Union

pregabalin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pregabalin Viatris Pharma (previously Pregabalin Pfizer)](#news-on)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Pregabalin Viatris Pharma is a medicine used to treat adults with the following conditions:

- neuropathic pain (pain due to nerve damage), including peripheral neuropathic pain, such as the pain experienced by patients with diabetes or herpes zoster (shingles), and central neuropathic pain, such as the pain experienced by patients who have had a spinal cord injury;
- epilepsy, where it is used as an 'add-on' to other epilepsy treatment in patients who have partial seizures (epileptic fits starting in one specific part of the brain);
- generalised anxiety disorder (long-term anxiety or nervousness about everyday matters).

This medicine is the same as Lyrica, which is already authorised in the European Union (EU). The company that makes Lyrica has agreed that its scientific data can be used for Pregabalin Viatris Pharma ('informed consent').

Expand section

Collapse section

## How is Pregabalin Viatris Pharma used?

Pregabalin Viatris Pharma is available as capsules and can only be obtained with a prescription. The recommended starting dose is divided into two or three doses. After three to seven days, the dose can be increased. Doses can be increased further until the most effective dose is reached. To stop treatment with Pregabalin Viatris Pharma the dose should be reduced gradually, over at least a week. Patients who have kidney problems may need to take lower doses.

For more information about using Pregabalin Viatris Pharma, see the package leaflet or contact your doctor or pharmacist.

## How does Pregabalin Viatris Pharma work?

The active substance in Pregabalin Viatris Pharma, pregabalin, is similar in structure to the body's own 'neurotransmitter' gamma-amino butyric acid (GABA), but has very different biological effects. Neurotransmitters are chemicals that allow nerve cells to communicate with each other. The exact way that pregabalin works is not fully understood, but it is thought to affect the way that calcium enters nerve cells. This reduces the activity of some of the nerve cells in the brain and spinal cord, reducing the release of other neurotransmitters that are involved in epilepsy and anxiety.

## What benefits of Pregabalin Viatris Pharma have been shown in studies?

Pregabalin Viatris Pharma has been compared with placebo (a dummy treatment) in 22 studies.

In neuropathic pain, the benefits of Pregabalin Viatris Pharma were evaluated for up to 12 weeks using a standard pain questionnaire. In 10 studies involving over 3,000 patients with peripheral neuropathic pain (either diabetic pain or shingles), 35% of the patients treated with Pregabalin Viatris Pharma had a decrease in pain scores of 50% or more, compared with 18% of the patients treated with placebo. In a smaller study involving 137 patients with central neuropathic pain due to a spinal cord injury, 22% of patients treated with Pregabalin Viatris Pharma had a decrease in pain scores of 50% or more, compared with 8% of the patients treated with placebo.

In epilepsy, the benefits of Pregabalin Viatris Pharma were evaluated in 3 studies involving 1,000 patients that looked at how much it reduced the number of seizures patients had after 11 to 12 weeks. About 45% of the patients taking 600 mg Pregabalin Viatris Pharma a day and about 35% of those taking 300 mg Pregabalin Viatris Pharma a day had a reduction in seizures of 50% or more. This compared with about 10% of the patients taking placebo.

Pregabalin Viatris Pharma was more effective than placebo in generalised anxiety disorder: in 8 studies involving over 3,000 patients, 52% of the patients taking Pregabalin Viatris Pharma had an improvement of 50% or more in their anxiety measured with a standard anxiety questionnaire, compared with 38% of the patients taking placebo.

## What are the risks associated with Pregabalin Viatris Pharma?

For the full list of side effects and restrictions with Pregabalin Viatris Pharma, see the package leaflet.

The most common side effects with Pregabalin Viatris Pharma (seen in more than 1 patient in 10) are dizziness and somnolence (sleepiness).

## Why is Pregabalin Viatris Pharma authorised in the EU?

The European Medicines Agency decided that Pregabalin Viatris Pharma's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Pregabalin Viatris Pharma?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pregabalin Viatris Pharma have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Pregabalin Viatris Pharma are continuously monitored. Suspected side effects reported with Pregabalin Viatris Pharma are carefully evaluated and any necessary action taken to protect patients.

## Other information about Pregabalin Viatris Pharma

Pregabalin Pfizer received a marketing authorisation valid throughout the EU on 25 June 2015.

The name of the medicine was changed to Pregabalin Viatris Pharma on 7 April 2025.

Pregabalin Pfizer : EPAR - Medicine overview

English (EN) (187.79 KB - PDF)

**First published:** 07/05/2014

**Last updated:** 27/06/2025

[View](/en/documents/overview/pregabalin-pfizer-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-659)

български (BG) (192.26 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/bg/documents/overview/pregabalin-pfizer-epar-medicine-overview_bg.pdf)

español (ES) (194.57 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/es/documents/overview/pregabalin-pfizer-epar-medicine-overview_es.pdf)

čeština (CS) (187.88 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/cs/documents/overview/pregabalin-pfizer-epar-medicine-overview_cs.pdf)

dansk (DA) (164.1 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/da/documents/overview/pregabalin-pfizer-epar-medicine-overview_da.pdf)

Deutsch (DE) (197.12 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/de/documents/overview/pregabalin-pfizer-epar-medicine-overview_de.pdf)

eesti keel (ET) (192.45 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/et/documents/overview/pregabalin-pfizer-epar-medicine-overview_et.pdf)

ελληνικά (EL) (220.73 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/el/documents/overview/pregabalin-pfizer-epar-medicine-overview_el.pdf)

français (FR) (196.07 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/fr/documents/overview/pregabalin-pfizer-epar-medicine-overview_fr.pdf)

hrvatski (HR) (187.71 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/hr/documents/overview/pregabalin-pfizer-epar-medicine-overview_hr.pdf)

italiano (IT) (164.41 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/it/documents/overview/pregabalin-pfizer-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (206.93 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/lv/documents/overview/pregabalin-pfizer-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (189.77 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/lt/documents/overview/pregabalin-pfizer-epar-medicine-overview_lt.pdf)

magyar (HU) (216.46 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/hu/documents/overview/pregabalin-pfizer-epar-medicine-overview_hu.pdf)

Malti (MT) (191.82 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/mt/documents/overview/pregabalin-pfizer-epar-medicine-overview_mt.pdf)

Nederlands (NL) (194.55 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/nl/documents/overview/pregabalin-pfizer-epar-medicine-overview_nl.pdf)

polski (PL) (220.57 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/pl/documents/overview/pregabalin-pfizer-epar-medicine-overview_pl.pdf)

português (PT) (165.99 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/pt/documents/overview/pregabalin-pfizer-epar-medicine-overview_pt.pdf)

română (RO) (216.19 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/ro/documents/overview/pregabalin-pfizer-epar-medicine-overview_ro.pdf)

slovenčina (SK) (188.88 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/sk/documents/overview/pregabalin-pfizer-epar-medicine-overview_sk.pdf)

slovenščina (SL) (215.4 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/sl/documents/overview/pregabalin-pfizer-epar-medicine-overview_sl.pdf)

Suomi (FI) (192.28 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/fi/documents/overview/pregabalin-pfizer-epar-medicine-overview_fi.pdf)

svenska (SV) (192.02 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

27/06/2025

[View](/sv/documents/overview/pregabalin-pfizer-epar-medicine-overview_sv.pdf)

Pregabalin Pfizer : EPAR - Risk-management-plan summary

English (EN) (1.03 MB - PDF)

**First published:** 17/12/2018

**Last updated:** 01/07/2024

[View](/en/documents/rmp-summary/pregabalin-pfizer-epar-risk-management-plan-summary_en.pdf)

## Product information

Pregabalin Viatris Pharma : EPAR - Product Information

English (EN) (661.4 KB - PDF)

**First published:** 07/05/2014

**Last updated:** 05/11/2025

[View](/en/documents/product-information/pregabalin-viatris-pharma-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-118)

български (BG) (686.93 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/bg/documents/product-information/pregabalin-viatris-pharma-epar-product-information_bg.pdf)

español (ES) (321.86 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/es/documents/product-information/pregabalin-viatris-pharma-epar-product-information_es.pdf)

čeština (CS) (501.71 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/cs/documents/product-information/pregabalin-viatris-pharma-epar-product-information_cs.pdf)

dansk (DA) (574.18 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/da/documents/product-information/pregabalin-viatris-pharma-epar-product-information_da.pdf)

Deutsch (DE) (448.36 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/de/documents/product-information/pregabalin-viatris-pharma-epar-product-information_de.pdf)

eesti keel (ET) (568.44 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/et/documents/product-information/pregabalin-viatris-pharma-epar-product-information_et.pdf)

ελληνικά (EL) (455.36 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/el/documents/product-information/pregabalin-viatris-pharma-epar-product-information_el.pdf)

français (FR) (571.88 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/fr/documents/product-information/pregabalin-viatris-pharma-epar-product-information_fr.pdf)

hrvatski (HR) (651.35 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/hr/documents/product-information/pregabalin-viatris-pharma-epar-product-information_hr.pdf)

íslenska (IS) (652.86 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/is/documents/product-information/pregabalin-viatris-pharma-epar-product-information_is.pdf)

italiano (IT) (321.87 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/it/documents/product-information/pregabalin-viatris-pharma-epar-product-information_it.pdf)

latviešu valoda (LV) (617.8 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/lv/documents/product-information/pregabalin-viatris-pharma-epar-product-information_lv.pdf)

lietuvių kalba (LT) (631.22 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/lt/documents/product-information/pregabalin-viatris-pharma-epar-product-information_lt.pdf)

magyar (HU) (685.88 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/hu/documents/product-information/pregabalin-viatris-pharma-epar-product-information_hu.pdf)

Malti (MT) (723.61 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/mt/documents/product-information/pregabalin-viatris-pharma-epar-product-information_mt.pdf)

Nederlands (NL) (575.92 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/nl/documents/product-information/pregabalin-viatris-pharma-epar-product-information_nl.pdf)

norsk (NO) (409.99 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/no/documents/product-information/pregabalin-viatris-pharma-epar-product-information_no.pdf)

polski (PL) (395.53 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/pl/documents/product-information/pregabalin-viatris-pharma-epar-product-information_pl.pdf)

português (PT) (435.55 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/pt/documents/product-information/pregabalin-viatris-pharma-epar-product-information_pt.pdf)

română (RO) (701.19 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/ro/documents/product-information/pregabalin-viatris-pharma-epar-product-information_ro.pdf)

slovenčina (SK) (659.13 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/sk/documents/product-information/pregabalin-viatris-pharma-epar-product-information_sk.pdf)

slovenščina (SL) (374.86 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/sl/documents/product-information/pregabalin-viatris-pharma-epar-product-information_sl.pdf)

Suomi (FI) (575.86 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/fi/documents/product-information/pregabalin-viatris-pharma-epar-product-information_fi.pdf)

svenska (SV) (564.15 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

05/11/2025

[View](/sv/documents/product-information/pregabalin-viatris-pharma-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000290223 05/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pregabalin Viatris Pharma : EPAR - All Authorised presentations

English (EN) (83.69 KB - PDF)

**First published:** 07/05/2014

**Last updated:** 08/04/2025

[View](/en/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-467)

български (BG) (75.2 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/bg/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_bg.pdf)

español (ES) (30.06 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/es/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_es.pdf)

čeština (CS) (70.43 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/cs/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (88.61 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/da/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (67.99 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/de/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (16.81 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/et/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (79.55 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/el/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_el.pdf)

français (FR) (57.03 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/fr/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (70.23 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/hr/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (109.38 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/is/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_is.pdf)

italiano (IT) (54.54 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/it/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (73.33 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/lv/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (115.59 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/lt/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (71.81 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/hu/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (75.58 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/mt/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (88.94 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/nl/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (57.83 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/no/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_no.pdf)

polski (PL) (67.85 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/pl/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_pl.pdf)

português (PT) (37.1 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/pt/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_pt.pdf)

română (RO) (102.33 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/ro/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (108.49 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/sk/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (60.95 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/sl/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (85.58 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/fi/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (73.54 KB - PDF)

**First published:**

07/05/2014

**Last updated:**

08/04/2025

[View](/sv/documents/all-authorised-presentations/pregabalin-viatris-pharma-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Pregabalin Viatris Pharma (previously Pregabalin Pfizer) Active substance pregabalin International non-proprietary name (INN) or common name pregabalin Therapeutic area (MeSH)

- Anxiety Disorders
- Epilepsy

Anatomical therapeutic chemical (ATC) code N02BF02

### Pharmacotherapeutic group

- Other analgesics and antipyretics
- Antiepileptics

### Therapeutic indication

Neuropathic pain Pregabalin Viatris Pharma is indicated for the treatment of peripheral and central neuropathic pain in adults.

Epilepsy Pregabalin Viatris Pharma is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Generalised Anxiety Disorder Pregabalin Viatris Pharma is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.

## Authorisation details

EMA product number EMEA/H/C/003880 Marketing authorisation holder

Viatris Healthcare Limited

Damastown Industrial Park Mulhuddart Dublin 15 Dublin Ireland

Opinion adopted 20/02/2014 Marketing authorisation issued 10/04/2014 Revision 38

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pregabalin Viatris Pharma : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (166.74 KB - PDF)

**First published:** 25/02/2025

**Last updated:** 05/11/2025

[View](/en/documents/procedural-steps-after/pregabalin-viatris-pharma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Pregabalin Pfizer : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (238.65 KB - PDF)

**First published:** 06/10/2014

**Last updated:** 03/07/2025

[View](/en/documents/procedural-steps-after/pregabalin-pfizer-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Pregabalin Pfizer-H-C-PSUSA-00002511-202301 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/440258/2023

English (EN) (129.66 KB - PDF)

**First published:** 15/12/2023

[View](/en/documents/scientific-conclusion/pregabalin-pfizer-h-c-psusa-00002511-202301-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Pregabalin Pfizer-H-C-PSUSA-00002511-202101: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/598198/2021

English (EN) (124.44 KB - PDF)

**First published:** 15/12/2021

[View](/en/documents/scientific-conclusion/pregabalin-pfizer-h-c-psusa-00002511-202101-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Pregabalin Pfizer-H-C-PSUSA-00002511-202001: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/523845/2020

English (EN) (152.65 KB - PDF)

**First published:** 27/11/2020

[View](/en/documents/scientific-conclusion/pregabalin-pfizer-h-c-psusa-00002511-202001-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Pregabalin Pfizer-H-C-3880-P46-004: EPAR - Assessment Report

Adopted

Reference Number: EMA/200865/2016

English (EN) (531.88 KB - PDF)

**First published:** 17/03/2016

**Last updated:** 17/03/2016

[View](/en/documents/variation-report/pregabalin-pfizer-h-c-3880-p46-004-epar-assessment-report_en.pdf)

Pregabalin Pfizer-H-C-3880-P46-0002 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/520162/2015

English (EN) (697.81 KB - PDF)

**First published:** 10/11/2015

**Last updated:** 10/11/2015

[View](/en/documents/variation-report/pregabalin-pfizer-h-c-3880-p46-0002-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Pregabalin Pfizer : EPAR - Public assessment report

Adopted

Reference Number: EMA/174304/2014

English (EN) (124.5 KB - PDF)

**First published:** 07/05/2014

**Last updated:** 07/05/2014

[View](/en/documents/assessment-report/pregabalin-pfizer-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pregabalin Pfizer

Adopted

Reference Number: EMA/87173/2014

English (EN) (63.39 KB - PDF)

**First published:** 21/02/2014

**Last updated:** 21/02/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pregabalin-pfizer_en.pdf)

#### News on Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 February 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-february-2014) 21/02/2014

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 05/11/2025

## Share this page

[Back to top](#main-content)